190 related articles for article (PubMed ID: 36926116)
1. Distinct IDH1/2-associated Methylation Profile and Enrichment of
Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
[TBL] [Abstract][Full Text] [Related]
2. Genomic Profiling Identifies Association of
Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
[TBL] [Abstract][Full Text] [Related]
3. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
Lucas CG; Grenert JP; Horvai A
Arch Pathol Lab Med; 2021 Aug; 145(8):1009-1017. PubMed ID: 33147331
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
[TBL] [Abstract][Full Text] [Related]
5. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
Denu RA; Yang RK; Lazar AJ; Patel SS; Lewis VO; Roszik J; Livingston JA; Wang WL; Shaw KR; Ratan R; Zarzour MA; Bird J; Raza S; Akdemir KC; Rodon Ahnert J; Subbiah V; Patel S; Conley AP
Clin Cancer Res; 2023 Dec; 29(23):4844-4852. PubMed ID: 37747813
[TBL] [Abstract][Full Text] [Related]
6. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
[TBL] [Abstract][Full Text] [Related]
7. Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.
Lam SW; van Langevelde K; Suurmeijer AJH; Cleven AHG; Bovée JVMG
Histopathology; 2019 Dec; 75(6):843-852. PubMed ID: 31297850
[TBL] [Abstract][Full Text] [Related]
8. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.
Kerr DA; Lopez HU; Deshpande V; Hornicek FJ; Duan Z; Zhang Y; Rosenberg AE; Borger DR; Nielsen GP
Am J Surg Pathol; 2013 Jun; 37(6):787-95. PubMed ID: 23598960
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas.
Amary MF; Ye H; Forbes G; Damato S; Maggiani F; Pollock R; Tirabosco R; Flanagan AM
Virchows Arch; 2015 Feb; 466(2):217-22. PubMed ID: 25432631
[TBL] [Abstract][Full Text] [Related]
10. Clonality analysis and
Yang T; Bai Y; Chen J; Sun K; Luo Y; Huang W; Zhang H
J Bone Oncol; 2020 Jun; 22():100293. PubMed ID: 32742915
[TBL] [Abstract][Full Text] [Related]
11. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma.
Meijer D; de Jong D; Pansuriya TC; van den Akker BE; Picci P; Szuhai K; Bovée JV
Genes Chromosomes Cancer; 2012 Oct; 51(10):899-909. PubMed ID: 22674453
[TBL] [Abstract][Full Text] [Related]
12. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
Amary MF; Bacsi K; Maggiani F; Damato S; Halai D; Berisha F; Pollock R; O'Donnell P; Grigoriadis A; Diss T; Eskandarpour M; Presneau N; Hogendoorn PC; Futreal A; Tirabosco R; Flanagan AM
J Pathol; 2011 Jul; 224(3):334-43. PubMed ID: 21598255
[TBL] [Abstract][Full Text] [Related]
13. Induction of sarcomas by mutant IDH2.
Lu C; Venneti S; Akalin A; Fang F; Ward PS; Dematteo RG; Intlekofer AM; Chen C; Ye J; Hameed M; Nafa K; Agaram NP; Cross JR; Khanin R; Mason CE; Healey JH; Lowe SW; Schwartz GK; Melnick A; Thompson CB
Genes Dev; 2013 Sep; 27(18):1986-98. PubMed ID: 24065766
[TBL] [Abstract][Full Text] [Related]
14. Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma.
Joseph NM; McGill KC; Horvai AE
Am J Surg Pathol; 2021 Jun; 45(6):812-819. PubMed ID: 33239505
[TBL] [Abstract][Full Text] [Related]
15. Targeted next-generation sequencing of dedifferentiated chondrosarcoma in the skull base reveals combined TP53 and PTEN mutations with increased proliferation index, an implication for pathogenesis.
Gao L; Hong X; Guo X; Cao D; Gao X; DeLaney TF; Gong X; Chen R; Ni J; Yao Y; Wang R; Chen X; Tian P; Xing B
Oncotarget; 2016 Jul; 7(28):43557-43569. PubMed ID: 27248819
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
[TBL] [Abstract][Full Text] [Related]
17. IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract.
Tallegas M; Miquelestorena-Standley É; Labit-Bouvier C; Badoual C; Francois A; Gomez-Brouchet A; Aubert S; Collin C; Tallet A; de Pinieux G
Hum Pathol; 2019 Feb; 84():183-191. PubMed ID: 30296521
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of IDH mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract][Full Text] [Related]
19. Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.
Vuong HG; Ngo TNM; Dunn IF
Cancer Med; 2021 Jul; 10(13):4415-4423. PubMed ID: 34085407
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
